A Dark Vector Cognition product

Item 16. Form 10-K Summary

6K characters. Original on sec.gov · Markdown

Item 16. Form 10-K Summary

Not applicable.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SignatureTitleDate
By:/s/ PRAHLAD SINGH, PhDPresident and Chief Executive OfficerFebruary 27, 2024
Prahlad Singh, PhD(Principal Executive Officer)
By:/s/ MAXWELL KRAKOWIAKSr. Vice President and Chief Financial OfficerFebruary 27, 2024
Maxwell Krakowiak(Principal Financial Officer)
By:/s/ ANITA GONZALESVice President and ControllerFebruary 27, 2024
Anita Gonzales(Principal Accounting Officer)

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Revvity, Inc., hereby severally constitute Prahlad Singh and Maxwell Krakowiak, and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names, in the capacities indicated below, this Annual Report on Form 10-K and any and all amendments to said Annual Report on Form 10-K, and generally to do all such things in our name and behalf in our capacities as officers and directors to enable Revvity, Inc. to comply with the provisions of the Securities Exchange Act of 1934, and all requirements of the Securities and Exchange Commission, hereby rectifying and confirming signed by our said attorneys, and any and all amendments thereto.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:

SignatureTitleDate
By:/s/ PRAHLAD SINGH, PhDPresident, Chief Executive Officer andFebruary 27, 2024
Prahlad Singh, PhDDirector (Principal Executive Officer)
By:/s/ MAXWELL KRAKOWIAKSr. Vice President andFebruary 27, 2024
Maxwell KrakowiakChief Financial Officer (Principal Financial Officer)
By:/s/ ANITA GONZALESVice President and ControllerFebruary 27, 2024
Anita Gonzales(Principal Accounting Officer)
By:/s/ PETER BARRETT, PhDDirectorFebruary 27, 2024
Peter Barrett, PhD
By:/s/ SAMUEL R. CHAPINDirectorFebruary 27, 2024
Samuel R. Chapin
By:/s/ SYLVIE GRÉGOIRE, PharmDDirectorFebruary 27, 2024
Sylvie Grégoire, PharmD
By:/s/ MICHAEL A. KLOBUCHARDirectorFebruary 27, 2024
Michael A. Klobuchar
By:/s/ MICHELLE MCMURRY-HEATH, MD PhDDirectorFebruary 27, 2024
Michelle McMurry-Heath, MD PhD
By:/s/ ALEXIS P. MICHASDirectorFebruary 27, 2024
Alexis P. Michas
By:/s SOPHIE V. VANDEBROEK, PhDDirectorFebruary 27, 2024
Sophie V. Vandebroek, PhD
By:/s/ MICHEL VOUNATSOSDirectorFebruary 27, 2024
Michel Vounatsos
By:/s/ FRANK WITNEY, PhDDirectorFebruary 27, 2024
Frank Witney, PhD
By:/s/ PASCALE WITZDirectorFebruary 27, 2024
Pascale Witz

Previous: Item 15. Exhibits and Financial Statement Schedules